Who
William Guyer
Chief Development Officer
Company insider
Files Form 4 as: Chief Development Officer, Corcept Therapeutics.
In numbers
- Trades disclosed
- 177
- Buys
- 0
- Sells
- 35
- Bought
- $0
- Sold
- $38.4M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Sep 2021
- Last trade
- 1 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 3 Sep 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Code A | $19K164 at $113.38 | filing |
| 1 Sep 2026filed 3 Sep 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —164 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Code A | $19K164 at $113.38 | filing |
| 1 Sep 2026filed 3 Sep 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —164 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Code M | $353K16,300 at $21.65 | filing |
| 10 Aug 2026filed 12 Aug 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $1.3M11,530 at $113.18 | filing |
| 10 Aug 2026filed 12 Aug 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $544K4,770 at $114.04 | filing |
| 10 Aug 2026filed 12 Aug 2026 | CORT Corcept Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —16,300 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | CORT Corcept Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —16,300 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Code M | $353K16,300 at $21.65 | filing |
| 10 Aug 2026filed 12 Aug 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $1.3M11,530 at $113.18 | filing |
| 10 Aug 2026filed 12 Aug 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $544K4,770 at $114.04 | filing |
| 4 Aug 2026filed 6 Aug 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Code M | $80K3,700 at $21.65 | filing |
| 4 Aug 2026filed 6 Aug 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $419K3,700 at $113.12 | filing |
| 4 Aug 2026filed 6 Aug 2026 | CORT Corcept Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,700 at $0.00 | filing |
| 4 Aug 2026filed 6 Aug 2026 | CORT Corcept Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,700 at $0.00 | filing |
| 4 Aug 2026filed 6 Aug 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Code M | $80K3,700 at $21.65 | filing |
| 4 Aug 2026filed 6 Aug 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $419K3,700 at $113.12 | filing |
| 7 Jul 2026filed 8 Jul 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Code M | $433K20,000 at $21.65 | filing |
| 7 Jul 2026filed 8 Jul 2026 | CORT Corcept TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $1.8M19,048 at $93.11 | filing |
News
No headline names them, or the companies they trade most, lately.